Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 160Other hematologic neoplasm 153Lymphoid 17Classical hematology 10Plasma cell 8Thoracic 4Genitourinary 3Gynecologic 2CNS 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia 2Glioblastoma 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Microsatellite Stable Colorectal Carcinoma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Flow Cytometry 3Psychiatric Rehabilitation 2Methylprednisolone 2Immunologic Techniques 2Azacitidine 2Alemtuzumab 2thymoglobulin 1sargramostim 1ruxolitinib 1rucaparib 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1aldesleukin 1abiraterone 1Zoledronic Acid 1Therapeutics 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1Rituximab 1Prednisone 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Moxifloxacin 1Microarray Analysis 1Interleukin-12 Subunit p35 1Interferon-alpha 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Azacitidine × Gynecologic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡